WuXi AppTec Raises 2025 Revenue Guidance After Half-Year Beat

WuXi AppTec Co. raised its full-year revenue forecast after strong gains in the US market contributed to a better-than-expected first-half performance, sending shares surging.

The Shanghai-based provider of global drug research, development and manufacturing services now expects 2025 revenue to be between 42.5-43.5 billion yuan ($5.9-6 billion), up from 41.5–43.0 billion yuan seen previously. That means year-on-year growth of 13%-17% versus the previous guidance of 10%-15%.